Managing HIV Drug Resistance
Author Information
Author(s): Cortez Karoll J., Maldarelli Frank
Primary Institution: HIV Drug Resistance Program, NCI, NIH
Hypothesis
How can clinical management effectively address HIV drug resistance?
Conclusion
Effective management of HIV drug resistance involves thorough evaluation and appropriate use of resistance testing to guide treatment.
Supporting Evidence
- Combination antiretroviral therapy has significantly reduced HIV morbidity and mortality.
- Drug resistance occurs in 7-15% of patients starting first-line therapy.
- Resistance testing can provide valuable information for treatment-experienced individuals.
Takeaway
Doctors need to check if HIV medicines are still working by testing for drug resistance, which helps them choose the best treatment for patients.
Methodology
The review discusses the emergence of drug resistance and the clinical evaluation and therapeutic options for individuals with rebound viremia during therapy.
Potential Biases
Potential bias due to the variability in patient adherence and the complexity of treatment regimens.
Limitations
The studies reviewed often had short durations and may not reflect long-term outcomes of resistance testing.
Participant Demographics
The study involved treatment-experienced individuals with HIV-1 infection.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website